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Abstract
Head and neck squamous cell carcinomas (HNSCCs)
are frequently characterized by chemotherapy and ra-
diation resistance and by overexpression of Bcl-XL, an
antiapoptotic member of the Bcl-2 protein family. In
this report, we examined whether cell-permeable pep-
tides derived from the BH3 domains of proapoptotic
Bax, Bad, or Bak could be used to target Bcl-XL and/or
Bcl-2 in HNSCC cells and induce apoptotic death in
these cells. To render the peptides cell-permeable,
Antennapedia (Ant) or polyarginine (R8) peptide trans-
duction domain was fused to the amino termini. Fluo-
rescence microscopy of peptide-treated HNSCC cells
revealed that the BH3 peptides colocalized with mito-
chondria, the site of Bcl-XL and Bcl-2 expression. By
contrast, a mutant peptide (BaxE BH3) that cannot
bind Bcl-XL or Bcl-2 was diffusely localized throughout
the cytoplasm. Treatment of three HNSCC cell lines
(1483, UM-22A, and UM-22B) with the wild-type BH3
peptides resulted in loss of viability and induction
of apoptosis, as assessed by 3-(4,5-dimethythiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assays and annexin V staining. In
general, Ant-conjugated peptidesweremore potent than
R8-conjugated peptides and Bad BH3 peptide was typi-
cally more potent than Bax BH3 or Bak BH3. Treatment
of purified HNSCC mitochondria with BH3 peptides re-
sulted in robust release of cytochrome c. Thus, the
relative apoptosis resistance of HNSCC cells is not due
to a deficit in this step of the intrinsic, mitochondrial-
mediated apoptosis pathway. We conclude that cell-
permeable BH3 peptides can be used to target Bcl-XL
and/or Bcl-2 in HNSCC and that targeting of these
proteins may have therapeutic value in the treatment of
this disease.
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Introduction
Approximately 40,000 cases of head and neck squamous
cell carcinoma (HNSCC) are diagnosed each year in the
United States and roughly 500,000 cases are reported world-
wide [1]. Standard treatment options for HNSCC include radi-
ation, surgery, and chemotherapy. However, HNSCCs typically
exhibit radiation and chemotherapy resistance, and 5-year
survival rates have lingered around 50% for several decades
[2,3]. Thus, there is a tremendous need to develop new thera-
peutic strategies for this disease.
The frequent resistance of HNSCC to radiation and chemo-
therapy is due, in large part, to aberrant inhibition of apoptosis
in the tumor cells. A number of signaling proteins and pathways
that contribute to cellular survival by blocking apoptosis have
been shown to be overexpressed and/or hyperactivated in
HNSCC, and include the epidermal growth factor receptor
(EGFR) [4,5], Akt kinase [6,7], mammalian target of rapamycin
[8], nuclear factor–nB (NF-nB) [9], and signal transducer and
activator of transcription-3 (STAT3) [10–12]. Targeting EGFR
with cetuximab monoclonal antibody, antisense oligonucleo-
tides, dominant-negative mutants, or the tyrosine kinase in-
hibitors gefitinib and erlotinib serves to attenuate signaling
downstream from the receptor and inhibits the proliferation and
survival of HNSCC in vitro and in vivo [5,13–15]. Similarly, tar-
geting of STAT3 or NF-nB with antisense, dominant-negatives,
small interfering RNA, or a STAT3 decoy oligonucleotide
promotes HNSCC cell apoptosis and enhances the sensitivities
of these cells to cisplatin, tumor necrosis factor–a, histone
deacetylase inhibitors, and radiation [10,16–22]. In addition,
treatment with rapamycin or small molecule inhibitors of Akt
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has been shown to induce apoptosis and tumor regression
in xenograft models of HNSCC [7,8,23]. The success of
these molecular targeting strategies in preclinical models of
HNSCC has raised hope for their successful application
in patients.
HNSCC cell lines and primary specimens are also char-
acterized by frequent overexpression of antiapoptotic mem-
bers of the Bcl-2 protein family, including Bcl-2 and Bcl-XL. In
particular, Bcl-XL is overexpressed in a large majority of
HNSCC and is associated with chemoresistance in this
disease [24]. The bcl-XL gene is a known downstream target
of STAT3 and NF-nB [25,26] and the overexpression of Bcl-
XL in HNSCC may be due to the aberrant activation of these
transcription factors. Antisense oligonucleotides directed
against Bcl-XL or Bcl-2 mRNA have been shown to activate
apoptosis and sensitize HNSCC cell lines to chemotherapy
drugs [27].
The Bcl-XL and Bcl-2 proteins act to inhibit chemotherapy-
and radiation-induced apoptosis by regulating the intrinsic,
mitochondrial-mediated pathway of apoptosis. Specifically,
Bcl-XL and Bcl-2 prevent chemotherapy- and radiation-
induced release of cytochrome c from mitochondria, thereby
preventing activation of the caspase protease cascade and
apoptotic destruction of the cell [28]. Bcl-XL and Bcl-2 exert
these effects by binding to the BH3 domains of proapoptotic
Bcl-2 family members such as Bax, Bad, and Bak, neutral-
izing the death-inducing effects of these proteins [28,29].
Recently, the small organic molecule gossypol has been
shown to bind to the BH3-binding pocket of Bcl-XL [30,31].
Treatment of HNSCC cells with ()-gossypol, the biologically
active enantiomer, has been shown to induce apoptosis and
promote chemosensitization [32–34]. However, it remains
uncertain whether the proapoptotic action of ()-gossypol in
HNSCC is due entirely to the inhibition of Bcl-XL and/or Bcl-2
[35]. Thus, evaluation of other highly specific agents is
needed to clearly validate the utility of Bcl-XL/Bcl-2 targeting
in HNSCC.
In the present study, we evaluated the ability of small
peptides derived from the BH3 domains of Bax, Bad, and
Bak to promote apoptosis signaling and death in HNSCC
cells. Previous studies have shown that short peptides
derived from the BH3 domains of proapoptotic proteins can
disrupt the heterodimerization of Bcl-XL and Bcl-2 with
proapoptotic binding partners in a highly specific fashion,
and induce apoptosis in leukemia and prostate cancer
models [36–42]. Our results show that following addition
to cells, the cell-permeable BH3 peptides localize to the
mitochondria, the subcellular site of Bcl-XL and Bcl-2 ex-
pression, supporting the ability of the peptides to specifically
target Bcl-XL and/or Bcl-2 in intact HNSCC cells. Peptide
treatment resulted in disruption of heterodimerization inter-
actions between pro- and antiapoptotic Bcl-2 family mem-
bers. The cell-permeable peptides also stimulated caspase
activation and apoptotic death in HNSCC cells, with Bad BH3
peptide exhibiting the most potent activity. Taken together,
our results indicate the potential therapeutic benefit of tar-
geting antiapoptotic members of the Bcl-2 protein family
in HNSCC.
Materials and Methods
Cell Lines and Reagents
The UM-22A, UM-22B, and 1483 cell lines were derived
from HNSCC and all are of human origin [43–46]. 1483
cells were provided by Dr. Gary Clayman (MD, Anderson
Cancer Center, Houston, TX), and UM-22A and UM-22B
were provided by Dr. Thomas Carey (University of Michigan,
Ann Arbor, MI). Cells were cultured at 37jC and 5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM; Mediatech,
Herndon, VA) containing 10% heat-inactivated fetal bo-
vine serum (FBS), 100 mg/ml penicillin–streptomycin, and
0.5 mg/ml amphotericin B. Jurkat T leukemic cells were
grown at 37jC and 5% CO2 in RPMI medium (BioWhitaker,
Walkersville, MD) containing 10% FBS, 100 mg/ml penicillin–
streptomycin, and 0.5 mg/ml amphotericin B. Peptides were
synthesized using a fluoren-9-ylmethoxycarbonyl synthesis
protocol on a peptide synthesizer (Pioneer; Applied Bio-
systems, Foster City, CA) by the University of Pittsburgh
Molecular Medicine Institute Peptide Synthesis Facility. Pep-
tides were dissolved in DMSO and stored at80jC. Hoechst
stain solution was purchased fromSigma (St. Louis, MO) and
MitoTrackerRed fromMolecular Probes (Invitrogen, Carlsbad,
CA). Streptavidin– fluorescein isothiocyanate (FITC) was
from Molecular Probes as well. 3-(4,5-Dimethythiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) reagent was obtained from Promega (Madison, WI).
Bio-Rad Protein Assay dye concentrate was purchased from
Bio-Rad (Hercules, CA). Anti –Bcl-2 antibody was from
DAKO (Carpinteria, CA) and anti–Bcl-XL antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti–poly(ADP)-ribose polymerase (PARP) antibody was
from Cell Signaling Technology (Danvers, MA). Anti–b-actin
antibody was from Sigma. Annexin V–FITC Apoptosis De-
tection Kits and anti–cytochrome c antibody were from BD
Pharmingen (San Diego, CA).
Fluorescence Microscopy
Fluorescence microscopy was used to examine the up-
take and subcellular distribution of BH3 peptides in HNSCC
cells. Cells were seeded onto glass coverslips (Fisher Sci-
entific, Pittsburgh, PA) at 1  104 cells per well in 24-well
plates, grown overnight in 10% FBS/DMEM medium, then
treated for varying lengths of time with biotinylated peptides
(25 mM) or the peptide diluent DMSO (0.25%). Cells were then
rinsed with cold PBS and incubated for 20 minutes at 37jC
with 500 nMMitoTracker Red to stain mitochondria. The cover-
slips were then washed three times with 500 ml of cold PBS,
and fixed with 3.7% paraformaldehyde for 30 minutes at 37jC.
After fixation, cells were washed three times with 500 ml cold
PBS, then permeabilized at room temperature with 2% para-
formaldehyde containing 0.1% Triton X-100. Following another
wash, the cells were incubated with 2 mg/ml streptavidin–FITC
for 30 minutes at room temperature. Cells were also stained
with 10 ng/ml Hoechst stain solution for 30 minutes at room
temperature to identify nuclei. The coverslips were then trans-
ferred to slides and cells were visualized by fluorescence
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microscopy (Nikon Eclipse E800; Quantitative Imaging Corp.,
Burnaby, British Columbia, Canada).
Cell Viability Assays
For viability assays, cells were seeded at a density of
10,000 cells per well in 96-well plates, incubated overnight
in 10% FBS/DMEM, washed with serum-free DMEM me-
dium, then treated for 24 hours with varying doses of pep-
tides in 100 ml of DMEM containing 1% FBS. Following
treatment, cells were incubated for 2 hours at 37jC with
20 ml of MTS reagent. Absorbance was measured at 490-nm
wavelength using a microplate reader (Bio-Tek Instruments,
Inc., Winooski, VT). Data were analyzed by GraphPad
PRISM version 4 software (San Diego, CA) to determine
IC50 values.
Immunoblotting
Cells were harvested by centrifugation for 5 minutes at
4jC then washed once with cold PBS. The cell pellets were
lysed for 10 minutes on ice in lysis buffer (50 mM Tris, pH 8.0,
150 mMNaCl, 0.1% SDS, and 1% NP-40) containing 3 mg/ml
leupeptin, 20 mg/ml aprotinin, and 1.5 mM PMSF. The lysates
were then pelleted at 11,000  g for 2 minutes at 4jC and
supernatants were transferred to new tubes. Protein con-
centrations were determined using Bio-Rad Protein Assay
dye concentrate. For detection of Bcl-2 and Bcl-XL, proteins
(40 mg per lane) were electrophoresed on 12.5% SDS–
PAGE gels. For detection of PARP cleavage products,
proteins (60 mg per lane) were electrophoresed on 7.5%
SDS–PAGE gels. Following electrophoresis, proteins were
transferred to nitrocellulose membranes for 3 hours at 45 V.
Membranes were blocked in 5% nonfat milk in TBST buffer
(10 mM Tris pH 8.0, 150 mM NaCl, and 0.1% Tween 20) at
room temperature for 1 hour, briefly washed with TBST
buffer, and probed with primary antibody overnight at 4jC.
After one 15-minute wash and three 5-minute washes in
TBST buffer, the membranes were incubated with secondary
antibody for 1 hour at room temperature. The membranes
were then washed once with TBST buffer for 15 minutes,
followed by three washes for 5 minutes each. The blots were
developed using enhanced chemiluminescence reagent, ac-
cording to the instructions of the manufacturer (PerkinElmer,
Boston, MA).
Flow Cytometry Analysis
Externalization of phosphatidylserine was assessed using
annexin V–FITC Apoptosis Detection Kits followed by flow
cytometry. Cells were seeded at 1.8  106 cells per 100-mm
dish, grown overnight in 10% FBS/DMEM, washed with
serum-free DMEM, then treated for 4 hours with 25 mM of
the peptides in 1% FBS/DMEM. Following incubation, cells
were washed with cold PBS and removed from the plates by
trypsinization. The resuspended cells were washed with
cold PBS and stained with FITC-conjugated annexin V anti-
body and propidium iodide (PI) according to the instruc-
tions provided by the manufacturer (Roche Applied Science,
Indianapolis, IN). Cells (50,000 per sample) were then
subjected to flow cytometric analysis using a flow cytom-
eter (Epics Coulter XL; Beckman-Coulter, Inc., Miami, FL)
equipped with a 488-nm argon laser and Expo 32 software
(Beckman-Coulter).
Mitochondria Isolation and Cytochrome c Release Assays
Mitochondria were isolated from healthy HNSCC cell lines
and Jurkat cells growing in 10% FBS/DMEM. When the cells
achieved approximately 80% confluence, 1  107 cells were
harvested by centrifugation for 8 minutes at 4jC. The cells
were washed once with cold PBS, centrifuged again, then
resuspended in 100 ml of resuspension buffer (20 mMHepes,
pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 250 mM
sucrose, 1 mM DTT, 1.5 mM PMSF, 3 mg/ml leupeptin, and
20 mg/ml aprotinin). The resuspended cells were then ho-
mogenized using a type B tight-clearance dounce homoge-
nizer (Wheaton, Millvale, NJ). The homogenized lysates
were centrifuged at 11,000  g for 30 minutes at 4jC to
pellet mitochondria. The pellets were washed in 100 ml of
resuspension buffer then centrifuged again at 11,000  g for
30 minutes at 4jC. The mitochondria-containing pellets were
resuspended in 100 ml of resuspension buffer and protein
concentrations were determined using Bio-Rad Protein As-
say dye concentrate. To perform cytochrome c release
assays, resuspended mitochondria (40 mg) were incubated
in the absence or presence of 25 mM of the BH3 peptides
or DMSO (2%) for 1 hour at 37jC. Following incubation,
the treated mitochondria were centrifuged at 11,000  g for
30 minutes at 4jC and the supernatants were transferred to
new tubes. The supernatants, containing proteins released
from the mitochondria, were then subjected to a second
centrifugation at 11,000  g for 30 minutes at 4jC to
eliminate potential contamination with intact mitochondria.
Aliquots of the supernatants (50 ml) were then electropho-
resed on 12.5% SDS–PAGE gels, transferred to nitrocellu-
lose membranes, and subjected to immunoblotting with
anti–cytochrome c antibody.
Results
Cell-Permeable Bax BH3 and Bad BH3 Peptides Localize
to Mitochondria in HNSCC Cells
To determine whether peptides corresponding to the BH3
domains of proapoptotic proteins could be used to target Bcl-
XL and/or Bcl-2 in HNSCC cells, fluorescence microscopy
was used to examine the subcellular localization of the
peptides in treated cells. Bcl-XL and Bcl-2 are known to be
expressed on the outer membrane of mitochondria. Thus,
agents that selectively bind and target Bcl-XL and Bcl-2
would be expected to localize to mitochondria. Figure 1A
depicts peptide localization in the HNSCC cell line UM-22B.
The peptides were made cell-permeable by conjugating the
16–amino acid Antennapedia (Ant) peptide transduction
domain [47] to the amino terminus of the 20–amino acid
Bax BH3 peptide and the 21–amino acid Bad BH3 peptide
(Table 1) [38,40]. As a control, Ant was also conjugated to the
amino terminus of a mutant version of Bax BH3 peptide
(termed BaxE), wherein a critical leucine residue in the
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Figure 1. Ant-Bax andAnt-Bad colocalizewithmitochondria and disrupt Bcl-2/Bax complexes in UM-22B cells. (A) UM-22B cells were seeded onto glass coverslips at
1 104 cells per well (24-well plates), grown overnight, and treated with 25 M biotinylated Ant-Bax, biotinylated Ant-Bad, biotinylated mutant peptide (Ant-BaxE), or
with 0.25%DMSO (peptide solvent). After 2 and 6 hours of treatment, cells were incubated with 500 nMMitoTracker Red to stainmitochondria (red). Following fixation
and permeabilization, cells were incubated with FITC-conjugated streptavidin to visualize peptide uptake (green). Cells were further incubated with Hoechst stain
solution to stain nuclei (blue) and were then examined by fluorescencemicroscopy. Amerged image (yellow) was used to detect colocalization of peptides (green) and
mitochondria (red). The results demonstrate colocalization of Ant-Bax and Ant-Bad peptides, but not mutant Ant-BaxE, with mitochondria. Disruption of cellular
morphologywas also observed in cells treatedwith Ant-Bax (6 hours) or Ant-Bad (2 and 6 hours). (B) UM-22B cells were seeded at 1 106 cells per 100-mmdish, then
treated for 2 hours in the absence or presence of 50 MAnt-Bad, Ant-Bax, or Ant-BaxE mutant peptide, or 0.25% DMSO alone. Whole cell lysates (2 106 cells per
lane) were prepared, then subjected to immunoprecipitation with anti-Bax polyclonal antibody, and followed by immunoblotting with anti –Bcl-2 monoclonal antibody.
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wild-type peptide was changed to a glutamate residue
[38,48]. In full-length Bax protein, mutation of this leucine
residue to glutamate has been shown to abolish the ability of
Bax to bind to antiapoptotic proteins and promote apoptosis
[48]. All three peptides (Ant-Bax, Ant-BaxE, and Ant-Bad)
were biotinylated, allowing fluorescent detection by strepta-
vidin–FITC. Mitochondria were stained using MitoTracker
Red dye and Hoechst staining was used to show nuclei. The
UM-22B cells were treated for 2 or 6 hours with peptides
(25 mM) or with 0.25% DMSO, the peptide diluent. As shown
(Figure 1A), after 2 hours of treatment, all three peptides
were detected in the cytoplasm of the treated cells. In the
case of Ant-Bad, and particularly Ant-Bax, the cytoplasmic
staining exhibited a punctate pattern similar to that observed
for MitoTracker Red staining of mitochondria. Conversely,
the mutant control peptide Ant-BaxE demonstrated diffuse
cytoplasmic staining. When fluorescence from the peptide
(green) and mitochondria (red) staining were merged, sub-
stantial yellow fluorescence was observed in cells treated
with Ant-Bad and Ant-Bax. This indicated that the Ant-Bad
and Ant-Bax peptides were localizing to the mitochondria,
the site of Bcl-XL and Bcl-2 expression. By contrast, no
yellow fluorescence was observed in cells treated with Ant-
BaxE, which is defective in its ability to bind to Bcl-XL or Bcl-
2. By 6 hours, robust levels of Ant-Bax and Ant-Bad were
observed in the cytoplasm and yellow fluorescence indica-
tive of peptide localization at the mitochondria was seen in
the merged images. Moreover, cells treated with Ant-Bax or
Ant-Bad for 6 hours exhibited altered morphology, with
accompanying apoptotic debris, particularly in cells treated
with Ant-Bad. Again, no mitochondrial localization (yellow
fluorescence) of the control peptide Ant-BaxE was seen after
6 hours, and Ant-BaxE–treated cells did not exhibit any
changes in morphology. Taken together, the fact that BH3
peptides capable of binding to Bcl-XL and Bcl-2 were local-
ized to the mitochondria, whereas a BH3 peptide that fails to
bind Bcl-XL and Bcl-2 did not localize to the mitochondria,
indicates that the Ant-Bax and Ant-Bad peptides were target-
ing Bcl-XL and Bcl-2 in the HNSCC cells. The disruption of
cellular morphology and the appearance of apoptotic debris
in the Ant-Bax– and Ant-Bad–treated cells further indicates
that targeting of Bcl-XL and/or Bcl-2 in HNSCC cells results in
induction of apoptotic death, a finding explored in greater
detail in subsequent experiments.
Cell-Permeable Bax BH3 and Bad BH3 Peptides Disrupt
Bcl-2/Bax Heterodimerization in Intact HNSCC Cells
To determine whether the cell-permeable BH3 peptides
could disrupt physical interactions between pro- and anti-
apoptotic Bcl-2 family members in intact HNSCC cells, we
performed coimmunoprecipitation experiments (Figure 1B).
UM-22B cells were treated in the absence or presence of
peptides, followed by immunoprecipitation with anti-Bax and
immunoblotting with anti–Bcl-2 to detect Bcl-2/Bax hetero-
dimerization complexes. Treatment of the cells with Ant-Bad
or Ant-Bax resulted in a substantial decrease in the levels of
intracellular Bcl-2/Bax, relative to untreated cells or cells
treated with DMSO alone. By contrast, treatment with the
mutant control peptide, Ant-BaxE, caused only a modest
decline in Bcl-2/Bax heterodimer levels. These findings
demonstrate that the wild-type BH3 peptides are capable
of displacing proapoptotic proteins bound to antiapoptotic
Bcl-2 family members in intact HNSCC cells.
Cell-Permeable BH3 Peptides Promote HNSCC Cell Death
We next examined whether cell-permeable BH3 peptides
could induce cell death in HNSCC cell lines (Figure 2).
Peptides corresponding to the BH3 domains of Bax, Bad,
and Bak, as well as mutant control Bax (BaxE), were made
cell-permeable by conjugating the Ant (Figure 2, A, C, and E)
or polyarginine (R8; Figure 2, B, D, and F ) peptide transduc-
tion domains to the amino termini of the peptides (Table 1).
The cell-permeable peptides were then used to treat three
different HNSCC cell lines, i.e., 1483, UM-22A, and UM-22B
[43–45]. In this panel, UM-22A cells represent cells derived
Figure 1. (continued)
Table 1. Cell-Permeable BH3 Peptides.
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from a primary HNSCC tumor, whereas UM-22B cells were
derived from a cervical lymph node metastasis in the same
patient. 1483 cells were also derived from a primary tumor.
Following treatment for 24 hours with varying doses of the
peptides, MTS assays were performed, and IC50 values were
determined (Table 2). As shown in Figure 2, the mutant control
peptides (Ant-BaxE or R8-BaxE) exhibited little, if any, killing
activity against the three HNSCC cell lines. By contrast, all
three wild-type peptides demonstrated some level of killing
activity. In general, peptides conjugated to Ant showed more
potent killing activity than the R8-conjugated peptides. In
addition, UM-22B cells exhibited greater resistance to the
BH3 peptides than 1483 or UM-22A cells, consistent with the
fact that UM-22B cells represent a more advanced, metastatic
disease stage. In the case of 1483 cells, all three Ant-BH3
peptides promoted cell death, with IC50 values of 18.2 mM,
24.8 mM, and 32.9 mM for Ant-Bax, Ant-Bad, and Ant-Bak,
respectively. In UM-22A cells, only Ant-Bad (IC50 = 18.3 mM)
and Ant-Bax (IC50 = 45.5 mM)were effective at killing, whereas
in UM-22B, only Ant-Bad (IC50 = 40.2 mM) exhibited activ-
ity. Similar results were obtained when Trypan Blue exclusion
assays were employed (not shown).
To determine whether the differing sensitivities of the
three HNSCC cell lines to the BH3 peptides may be due to
different levels of expression of Bcl-XL or Bcl-2, we performed
immunoblotting with anti–Bcl-XL or anti–Bcl-2 (Figure 3).
Bcl-XL has been reported to be frequently overexpressed
in primary HNSCC specimens [24]. Consistent with this, all
three cell lines were found to express abundant levels of the
Bcl-XL protein. 1483 cells had the lowest Bcl-XL levels, cor-
relating with the greater sensitivity of this cell line to the BH3
peptides. Bcl-2 levels varied among the three cell lines, with
UM-22B cells exhibiting the highest expression. The high
levels of Bcl-XL and Bcl-2 found in UM-22B cells correlated
with the greater resistance of these cells to the BH3 pep-
tides. In addition, it is interesting to note that, whereas the
Bcl-XL levels in UM-22A and UM-22B were comparable,
Bcl-2 expression was dramatically higher in UM-22B cells.
This suggests, in this case, that conversion to a metastatic
phenotype was associated with the acquisition of Bcl-2 over-
expression status.
Figure 2. Antennapedia (Ant)- and polyarginine (R8)-conjugated BH3
domains of Bax, Bad, and Bak promote loss of HNSCC cell viability. 1483
(A and B), UM-22A (C and D), and UM-22B (E and F) cells were seeded into
96-well plates, grown overnight, then treated for 24 hours with varying doses
of Ant- or R8-conjugated peptides in 1% FBS/DMEM medium. Following
treatment, cells were analyzed using MTS assays. Each data point repre-
sents the average from triplicate wells and error bars represent standard
deviations. Data were plotted as the percent of metabolic activity relative to
untreated cells. IC50 values were calculated as described in the Materials
and Methods section, and they are shown for Ant-conjugated peptides in
Table 2. The experiments were performed three times, with similar results
each time.
Table 2. IC50 Values of Ant-Conjugated Peptides.
IC50 (mM)
Ant-Bad 24.8
1483 Ant-Bax 18.2
Ant-Bak 32.9
Ant-Bad 18.3
UM-22A Ant-Bax 45.5
Ant-Bak 82
Ant-Bad 40.2
UM-22B Ant-Bax > 100
Ant-Bak > 100
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To determine whether the reduced killing activity of R8-
conjugated peptides relative to Ant-conjugated peptides was
due to reduced cellular uptake of the R8-conjugated pep-
tides, we employed flow cytometry to assess peptide uptake
(Figure W1). Cells were left untreated or were treated for
45 minutes with DMSO, biotinylated R8-Bax, or biotinylated
Ant-Bax. Streptavidin–FITC and flow cytometry were then
used to determine the percentage of cells that had taken up
peptide. Surprisingly, whereas 50.4% of cells scored posi-
tive for uptake of R8-Bax in this experiment, only 23.0% of
cells scored positive for Ant-Bax uptake (see Figure W1).
The more efficient uptake, but reduced killing activity, of the
R8-conjugated BH3 peptides suggests that these peptides
may have reduced affinities for Bcl-XL and/or Bcl-2 com-
pared with the Ant-conjugated versions.
BH3 Peptides Induce HNSCC Apoptosis
Agents that directly target and inhibit antiapoptotic proteins
such as Bcl-XL and Bcl-2 might be expected to predispose
a cell to apoptosis, or to directly activate apoptotic death.
To determine whether the cell-permeable BH3 peptides acti-
vated an apoptotic form of cell death, HNSCC cell lines were
exposed to peptides, then analyzed by flow cytometry for
annexin V and PI staining. Annexin V staining serves as a
measure of phosphatidylserine externalization, and cells that
are annexin V+/PI represent early apoptotic cells [49,50].
A representative experiment is shown in Figure 4A, in which
UM-22A cells were treated with 25 mM peptide for 4 hours.
As shown, the appearance of early apoptotic cells (annexin
V+/PI) is seen in cells treated with Ant-Bax, Ant-Bad, or Ant-
Bak. By contrast, cells that were either untreated, or were
treated with 0.25% DMSO or the control peptide Ant-BaxE
(25 mM) showed no appreciable signs of apoptosis induction.
After 4 hours of treatment, the Ant-Bad peptide produced
the highest levels of apoptosis (31.7%), consistent with the
results from MTS assays (Figure 2C). Similar results were
seen in cells treated with peptides for 3 hours (data not
shown). Longer treatment times were needed to observe high
levels of apoptosis in Ant-Bax–treated cells (data not shown).
However, Ant-BaxE mutant peptide failed to induce apoptosis
even after prolonged incubation.
The induction of apoptotic death is also characterized by
the activation of caspase proteases, and the cleavage of
caspase substrate proteins. Caspase-3, a major executioner
caspase, is known to cleave PARP, a 116-kDa protein, to frag-
ments of 89 and 24 kDa [51]. To determine whether treatment
with the cell-permeable BH3 peptides resulted in caspase
protease activation, treated HNSCC cells were analyzed by
immunoblotting with anti-PARP antibody. A representative ex-
periment using UM-22A cells treated for 90 minutes is shown
in Figure 4B. Appearance of the 89-kDa PARP fragment
was clearly visible in cells treated with Ant-Bad or Ant-Bak,
although longer treatment times were needed to detect sub-
stantial PARP cleavage in Ant-Bax–treated cells. Taken to-
gether, our flow cytometric analyses and PARP cleavage
analyses demonstrate that the cell-permeable BH3 peptides
induce apoptotic cell death in HNSCC cells.
HNSCC Cells Are Not Defective in
Mitochondrial-Mediated Apoptosis
We and others have previously reported that BH3 pep-
tides potently kill chemotherapy-sensitive hematopoietic cell
lines with IC50 values in the low micromolar range [39,40,52].
As shown in Figure 5A, when Jurkat T leukemic cells were
treated for 48 hours with Ant-Bad or Ant-Bax, IC50 values
of 3.8 mM and 5.6 mM, respectively, were observed. Much
higher concentrations were needed to kill HNSCC cell lines
(Figure 2 and Table 2). Because HNSCC cells are typi-
cally more resistant to chemotherapy drugs and because
chemotherapy-induced apoptosis is known to be mediated
by the mitochondrial or intrinsic apoptosis pathway [53], this
raised the possibility that HNSCC cells may be defective
in mitochondrial-mediated apoptosis signaling. To determine
whether the reduced responsiveness of HNSCC cell lines to
BH3 peptides was due to defective mitochondrial signaling,
we isolated mitochondria from the three HNSCC cell lines
and from Jurkat cells. The isolated mitochondria were then
treated with peptides and the release of cytochrome c from
mitochondria was assessed by immunoblotting of the super-
natants (Figure 5B). The release of cytochrome c into cytosol
represents a key step during the intrinsic, mitochondrial-
mediated pathway of apoptosis [28,54]. As shown in Fig-
ure 5B, Ant-Bax, Ant-Bad, and Ant-Bak induced potent re-
lease of cytochrome c from the HNSCC mitochondria. By
contrast, only negligible release was detected from HNSCC
mitochondria treated with DMSO or the control peptide Ant-
BaxE. These data were confirmed by immunoblotting of
the mitochondrial pellets to show depletion of mitochondrial
Figure 3. Bcl-2 and Bcl-XL expression levels in HNSCC cell lines. Whole
cell protein extracts (40 g per lane) from 1483, UM-22A, and UM-22B cells
were subjected to immunoblotting with anti –Bcl-2 or anti –Bcl-XL antibodies.
Membranes were stripped and reprobed with anti –-actin to demonstrate
equal loading.
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cytochrome c by the wild-type peptides (Figure 5B). Col-
lectively, these results provide further support for the con-
tention that the wild-type BH3 peptides directly target and
inhibit Bcl-XL and/or Bcl-2 on the surface of HNSCC mito-
chondria. In the case of isolated Jurkat mitochondria, the
background levels of cytochrome c release detected in un-
treated, DMSO-treated, and Ant-BaxE–treated were signif-
icantly elevated. However, when shorter exposures of the gel
were used to reduce the intensity of the background bands
(compare 20-second exposure for Jurkat mitochondria with
1-minute exposure for HNSCC mitochondria), it can be seen
that the induction of cytochrome c release by wild-type BH3
peptides is roughly comparable between Jurkat mitochondria
and mitochondria from the HNSCC cell lines. This indicates
that HNSCC cells are not defective in this key step in the
intrinsic, mitochondrial-mediated apoptosis pathway.
Discussion
HNSCC is a common human cancer with poor 5-year
survival rates [1–3]. A major underlying problem in the
treatment of HNSCC is the inherent resistance of the cancer
cells to chemotherapy and radiation. This resistance is
caused, in large part, by the aberrant inhibition of apoptosis
signaling. In this report we sought to determine whether
direct targeting of Bcl-XL and/or Bcl-2 would promote apop-
tosis induction in HNSCC cells. Although previous reports
have shown that ()-gossypol, a small organic molecule that
Figure 4. Cell-permeable BH3 peptides activate apoptotic signaling and cell death. (A) UM-22A cells were seeded at 1.8  106 cells per 100-mm dish, grown
overnight, treated for 4 hours with 0.25% DMSO or with 25 M Ant-Bax, Ant-Bad, Ant-Bak, or Ant-BaxE peptides. Following incubation, cells were stained with
annexin V–FITC and PI and subjected to flow cytometric analysis. (B) Cell-permeable BH3 peptides induce caspase protease activation in HNSCC cells. UM-22A
cells were seeded at 1.8  106 cells per 100-mm dish, grown overnight, and then treated for 90 minutes with 0.5% DMSO or with 50 M Ant-BaxE, Ant-Bax, Ant-
Bad, or Ant-Bak. Following incubation, whole cell lysates were prepared and subjected to immunoblotting with anti-PARP antibody. A representative example of
three independent experiments is shown.
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binds Bcl-XL, promotes apoptosis in HNSCC cells [32–34], it
has been difficult to validate Bcl-XL and/or Bcl-2 as the
primary targets of ()-gossypol in intact HNSCC cells [35].
The BH3 peptides used in our studies offer the advantage
that they can be labeled with biotin and be detected with
streptavidin–FITC to demonstrate colocalization with the
site of Bcl-XL/Bcl-2 expression. In addition, BH3 peptides
derived from proapoptotic proteins are highly specific for
binding to antiapoptotic members of the Bcl-2 protein family
[38,39,42,53,55–57]. Our results show that wild-type BH3
peptides colocalize with mitochondria in intact HNSCC cells,
the site of Bcl-XL and Bcl-2 expression (Figure 1A). The fact
that a mutant BH3 peptide (Ant-BaxE) incapable of binding to
Bcl-XL or Bcl-2 no longer localized to mitochondria strongly
supports the contention that the wild-type BH3 peptides
directly targeted Bcl-XL and/or Bcl-2 in intact HNSCC cells.
This was supported by the finding that wild-type, and not
mutant, peptides caused physical disruption of Bcl-2/Bax
complexes in intact cells (Figure 1B). In addition, the wild-
type Bax, Bad, and Bak BH3 peptides, and not the BaxE
mutant peptide, were able to promote cytochrome c release
from isolated HNSCC mitochondria (Figure 5). Together,
these experiments indicate direct intracellular targeting of
Bcl-XL and/or Bcl-2 by the cell-permeable BH3 peptides.
Treatment of the three different HNSCC cell lines with the
cell-permeable BH3 peptides resulted in activation of apop-
tosis signaling, as evidenced by phosphatidylserine externali-
zation (annexin V staining) and PARP cleavage (Figure 4).
Ultimately, loss of viability and cell death were observed (Fig-
ure 2). Thus, utilization of the BH3 peptides provided clear
demonstration that direct targeting of Bcl-XL and/or Bcl-2 in
HNSCC cells leads to apoptosis induction. Comparison of
the different peptides revealed that Ant-conjugated peptides
were generally more efficacious at killing HNSCC cells than
the R8-conjugated peptides. By contrast, R8-conjugated pep-
tides appear to be taken up with slightly greater efficiency
than the Ant-conjugated peptides. This suggests that con-
jugation to the Ant or R8 peptide transduction domains may
differentially alter the affinities of the BH3 peptides for Bcl-XL
and/or Bcl-2.
We also observed that the cell-permeable Bad BH3
peptide was usually the most potent peptide for inducing
apoptosis signaling and cell death. Prior studies have shown
that full-length Bad protein and Bad BH3 peptide bind with
higher affinity to Bcl-XL than to Bcl-2 [58,59]. Because Bcl-XL
appears to be more highly overexpressed in the HNSCC cell
lines we employed (Figure 3), an agent that exhibits prefer-
ential binding for Bcl-XL might be predicted to exert more
potent biological effects, as was observed in the case of Bad
BH3. Other studies using in vitro binding assays have shown
that Bad BH3 peptide is more efficacious than Bax BH3
peptide at disrupting interactions between Bcl-XL and Bax
proteins [38,40]. Because Bcl-XL overexpression is more
common than Bcl-2 overexpression in HNSCC primary
Figure 5. BH3 peptides induce comparable cytochrome c release from mitochondria isolated from chemosensitive Jurkat cells and chemoresistant HNSCC cells.
(A) Cell-permeable BH3 peptides are potently active at killing Jurkat T leukemic cells. Jurkat cells were seeded at 1  105 cells/ml in 96-well plates in triplicate,
grown overnight, and then treated with varying doses of Ant-Bad, Ant-Bax, or Ant-BaxE mutant peptide, as well as with Ant peptide alone. Following incubation,
cells were analyzed using MTS assays as described in Figure 2. (B) Induction of cytochrome c release from mitochondria isolated from Jurkat, UM-22A, 1483, and
UM-22B cells. Isolated mitochondria (40 g per sample) were incubated for 1 hour at 37jC with 25 M Ant-Bax, Ant-Bad, Ant-Bak, or the mutant control peptide,
Ant-BaxE. Following incubation, the mitochondria were pelleted to obtain supernatants containing released cytochrome c. The supernatants and mitochondrial
pellets were electrophoresed on 12.5% SDS–PAGE gels, transferred to nitrocellulose, and probed with anti – cytochrome c (Cyt. C). The experiment was
performed three times, with similar results each time.
Targeting Bcl-XL/Bcl-2 in HNSCC with BH3 Peptides Li et al. 809
Neoplasia . Vol. 9, No. 10, 2007
specimens [24,60], it may be useful to focus on the Bad BH3
peptide for future efforts aimed at optimization and genera-
tion of derivatives or analogs.
The application of peptidic agents to the treatment of
cancer is complicated by issues of size, stability, and uptake
of the peptides or peptidomimetic derivatives. Nonetheless,
our studies using BH3 peptides demonstrate that specific
targeting of antiapoptotic Bcl-2 family members can be used
to enhance the apoptotic sensitivities of HNSCC cells. Our
findings support investigation in HNSCC of novel small
molecule inhibitors of Bcl-XL and/or Bcl-2, including agents
such as ABT-737 and A-385358 which exhibit highly potent
activities against solid tumor cell lines [61,62]. The eventual
clinical application of highly specific and potent Bcl-XL/Bcl-2
targeting agentsmay have significant therapeutic value in the
treatment of chemotherapy- and radiation-resistant HNSCC.
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Figure W1. Efficiency of Ant-Bax and R8-Bax uptake by HNSCC cells. UM-22B cells were plated at 1  106 cells per 100-mm dish, then treated for 45 minutes with
25 M biotinylated Ant-Bax or biotinylated R8-Bax, or DMSO alone. The treated cells were harvested, fixed, permeabilized, then treated for 30 minutes with 2 g/ml
streptavidin –FITC. Flow cytometry was used to determine the percent of cells scoring positive for peptide uptake (indicated in parentheses).
